Embedded Files
Research material and lot documents.
Retatrutide, also called reta or the reta peptide, is an investigational once-weekly triple hormone receptor agonist that Eli Lilly is testing in phase 3 trials. Laboratory material appears in Curo's Reta 10mg Kit listing.
What is retatrutide?
What is retatrutide?
Retatrutide is a single molecule that activates the receptors for three hormones: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. Eli Lilly's page of September 29, 2026 says it is investigational and "not yet available for public use." Lilly is studying it in phase 3 trials for obesity, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes and metabolic dysfunction-associated steatotic liver disease. Source: Lilly, What to know about retatrutide.
Lilly's development code for the molecule is LY3437943 (PMID 37366315). Reta and RTA are short forms that some supplier listings use, such as the product name RTA-GLP3 (RETA) in Curo's lot certificates. The nickname GLP-3 has its own page: GLP-3 and retatrutide.
How does retatrutide work?
How does retatrutide work?
The 2022 paper that described the molecule, then coded LY3437943, reported its receptor activity and early tests. In cell assays the authors found balanced glucagon-receptor and GLP-1-receptor activity, with more GIP-receptor activity. In obese mice the molecule lowered body weight and improved glycemic control. The authors attributed the added weight loss in mice to glucagon-receptor energy expenditure on top of the lower calorie intake driven by the GIP and GLP-1 receptors. Source: 2022 Cell Metabolism paper, PMID 35985340.
What is the retatrutide peptide made of?
What is the retatrutide peptide made of?
FDA's substance record lists retatrutide under UNII NOP2Y096GV, with the CAS number 2381089-83-2, the codes LY-3437943 and LY3437943, and the INN and USAN names. Its chemical name describes an amino-acid chain with a fatty-acid side chain attached to a lysine residue. Source: FDA UNII record for retatrutide.
PubChem lists the formula C221H342N46O68, a computed molecular weight of 4731 g/mol and an exact mass of 4730.4785. Source: PubChem record, CID 171390338. These are reference values for the molecule. A vial's label still needs a matching lot report, which the retatrutide research peptide page covers.
What is the half-life of retatrutide?
What is the half-life of retatrutide?
A 12-week phase 1b trial in 72 adults with type 2 diabetes (NCT04143802) reported a half-life of approximately 6 days. The authors also reported that gastrointestinal disorders were the most frequently reported treatment-emergent adverse events. Source: 2022 Lancet phase 1b trial, PMID 36354040.
Where does retatrutide stand in development?
Where does retatrutide stand in development?
ClinicalTrials.gov lists Eli Lilly and Company as sponsor of each study below.
March 2019: the first registered study, NCT03841630, started in 45 healthy participants.
May 2021: phase 2 trials started in obesity or overweight (NCT04881760, 338 adults) and in type 2 diabetes (NCT04867785, 281 adults). Both were published in 2023.
2023 and 2024: the phase 3 TRIUMPH and TRANSCEND-T2D trials started, and papers on three of them appeared in 2026 (PMID 42814954, PMID 42810372 and PMID 42250575).
The retatrutide trials page follows each result. The retatrutide FDA approval page gives Lilly's stated plan for an application to FDA.
Open the retatrutide source ledger.
Is retatrutide approved?
Is retatrutide approved?
Eli Lilly's page of September 29, 2026 says retatrutide "is not currently approved by the FDA and is considered an investigational medication." Source: Lilly, What to know about retatrutide. The retatrutide FDA approval page quotes Lilly and FDA in full.
Where are the trial results, side effects and comparisons?
Where are the trial results, side effects and comparisons?
The retatrutide trials page follows each published phase 2 and phase 3 result. The retatrutide side effects page repeats the adverse events that the authors reported. Retatrutide vs tirzepatide covers the two molecules and the trial that compares them.
Where are the lot documents for retatrutide research material?
Where are the lot documents for retatrutide research material?
The retatrutide research peptide page explains what to read in a lot report. For the reports themselves, open Curo's lot certificates.
Page updated
Google Sites
Report abuse